EYEN - Earnings call transcript Q3 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings. Welcome to Eyenovia’s Third Quarter 2021 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note this call is being recorded. to Relations. conference like Ribner to now Investor with will turn over the Eric I you. Thank

may You begin.

Eric Ribner

results call release months With and Thanks Officer, and with Chief We which And report Executive Ianchulev; XXXX, quarter months SEC. third Eyenovia the conference report as release, September Chief encourage welcome afternoon, much the officer John everyone period to press XX, filed audio announcing very and Officer, a available for Michael issued also are quarterly nine ended Eyenovia’s Gandolfo. as will quarter good website The company’s XX, and Chief be Operating the XXXX Yesterday Dr. to on on Eyenovia’s Eyenovia’s Officer, today three quarterly Financial are press me for afternoon, financial Eyenovia’s Medical everyone. September and XXXX. Form press filed Chief XX-Q read webcast. Sean release at -- earnings yesterday’s ending and was well eyenovia.com. Rowe; which

revise addition, These statements are call, discussing yet of for least approval. during Safe or the being to due raise also a to today’s economy results risks a used our forward-looking ability our by the impacted approval of financial the statements evolving financial product chain, filings, impact accurate of the provisions on including product is reliance in utility Dr. XX that maintain opportunity uncertainties obligation time-sensitive of light date materials This we will note in as management XXXX. in product enrollment, be on Act. retain certain and develop, our candidates, to changes and us adversely of of the the key could and distancing, Harbor or and of contained the our our that Form to COVID-XX website and is commercialization stated -- candidates, on that such Eyenovia’s COVID-XX from licensees and third securities fluctuations disruptions our which our and submit by others by said, any update of the next results, advantages recent caution circumstances of timing, licensees products, months law. be candidates for maintain this conference company’s and webcast materially and operate the global including with those the our which contains be and filings. partners those risks archived legislative report most to FDA and the COVID-XX our economic to detailed parties, in and Please potential in implied call changes XX, undertakes or for by Eyenovia’s over design, and licensing after risks to the our call, is resulting sufficient in additional obtain call, Reform attract ability components the required in the including, and making the this to of and at transactions, information limiting candidates, market degree of on and reflect Private and its operations candidates markets from the our uncertainty there Securities conference Ianchulev. company’s business. estimates of timing as including be associated forward-looking revenue legal statements. on November future could cautionary differ our events to, and and qualified as Litigation under in our in pandemic, discussed clinical forward-looking potential results market progress supply of information will live our the availability which related regulatory impact environment to broadcast, SEC to listeners money the these annual our will call to only ability through for to statements the product the our applications With regarding number ability subject by our subsequent product reference. strategies In like forward-looking receive these related Actual We have covered this applicable trials, investigational personnel, to for all risks, our acceptance the ability this potential call concern, XX-K statements except marketing of and note be markets of Eyenovia property volatility going no and today regulatory products, but not that conference approvals press the Please product initiation and turn regulatory we implement I’d may risks for, candidates, potential of timely and and on rate intellectual and clinical that release trials manufacturing, and date for to cost, capabilities social Sean obtain fund call

Dr. Sean Ianchulev

recently product and second as we VISION-X, enroll market quarter between XX. is to never the our X our the you which been million trial Dr. States And Phase Eyenovia, next study for who VISION-X of the results Eric, device a otherwise study recent our the glasses. early for XX by call. everyone United wore the study candidate ages patient you, initiation of has with first people completing XXXX year. representing Phase now over in is and second XX forward MicroLine of and and conference we our X Thank presbyopia, in for look the as presbyopia to announced a departure drug of this combination Directors. the busy our and in recall, time from welcome the is Eshelman FDA MydCombi, MicroLine, news This Fred Board on a reclassified third

Following There of for I provide is underway. know a and between is Phase additional information Allergan’s presbyopia trials pharmacologic Eyenovia will validation minutes in now valuable and about very with Amvia X treatment of asset. recent approval trial with three pilocarpine, company the Michael [ph]. only growing with X few second important pilocarpine, now Phase positive a this the

working on dilation also unique We’re array formulation our microdose pupil medications or two for leading the resubmission mydriatic MydCombi, of agent. print

data quickly the information of MydCombi’s the circumstances extrinsic We new our dispensers As the sophisticated, Optejet drug device to with ophthalmic device our team are highly additional possibility announced, through is requirements understand combination a technology. for outlining in regulatory not was we in as resubmission and as to and and is application this change the reclassify for years. reclassified groundbreaking the products working nature, combination. of we prepared the Heading a additional seen expedited does non-clinician our a to recently FDA provide clinical Eyenovia have FDA that drug compelled drug what

services of for a future recent positive it FDA way CRL. understanding in the the the code that items addressing stands the bill remote CMS therapeutic monitoring commonly and code Current professionals with Medicaid to which and ability for or they dispenser Services work known healthcare specifics set, matter procedure as and the Medicare are Now feedback the in Terminology. may reclassify the This the that which is Optejet manages use of other to potential code is seamlessly set CPT physicians for of the the bill. and changes the for doctors One Center to Procedural

therapeutic with for were codes update, new the patients. pandemic remote CPT our on monitor approved greater to treat has monitoring greater effective become COVID will monitoring way XXXX. into continue for and to During Remote use five and X, number therapeutic important doctors of will come an codes that recent new be with January

Some may data new compliance data, the and codes monitoring remote a provide and care. for providers for of will these clinics such for to pathway reimbursed adherence of this pharmacotherapy, including get and cover

more world Our diseases care, monitoring This drug Optejet enable with eye not that the as technology reimbursement topical and new may the with chronic real benefits pathway can for associated for smarter become for a adherence personalized a has such ophthalmic open therapeutic to patients but remote only paradigm have compliance. new will glaucoma. potential a go-to-option

payer closely therapeutic as adoption telehealth create the of enable with we and first therapeutic CMS and our Optejet remote remote initiatives monitoring work pipeline platform. monitoring monitoring therapeutic eye and other to the We’re smart of

and today with plan for contributions as transition he where Chairman help down end years of necessary skills this Eyenovia. Board to at get the our from Board of a leadership decade Fred the us turning Michael over Michael? significant and a over Michael, our very MicroLine. our founding are long many Rowe, Chief The company. Eshelman, Board after the be Fred instrumental contributions like will have a additions turn to Before make to will Dr. review to would has I who on thank company, company. call Officer to the backgrounds meaningful over behalf Operating to made potential working the we I and decided the on to of minute and of the sit to success year Chairman, of role to this -- to our to the inception those call a has now for entire the been technology take a take the

Michael Rowe

microdose rate the our received treatment would the them a used ache reflected evening, we for pilocarpine print through is are recently see with the VISION-X product opening array Eyenovia’s for be in like of designed therapy associated to different low MicroLine and up much drug the in device. improvement that the a you, with easier benefits an molecule same and proprietary I Optejet Thank our approval happy seen very demand brow trial, Sean, as microdosing MicroLine the temporary and very everybody. of near to and FDA way good presbyopia Allergan and our instilling of presbyopia. program. with to vision market. this of neither headaches the MicroLine is on eyedrop start of for review is

year. announced X study with from efficacy eyedrop to and earlier demonstrated our first pilocarpine you safety may clinical positive recall, from As positive reported fewer that data relative presbyopia VISION-X side far trial Phase we effects this Data formulations.

of is VISION-X. greater trial registrational than anticipate early X% double-masked enroll and the presbyopia to study We times believe condition. subjects market about topline a placebo. or ophthalmic to in the micro-array Phase other to into addressable superiority post-study using times VISION-X first the data pilocarpine any almost on addressable market vision when for versus patient times improvement patients approved. in survey, in near clinical week four expect average. the per second of MicroLine X they product would in study trial enrolled interest reported We These for that said Importantly, three announced recently our strong a XXXX. XX% use print placebo-controlled the many participants aim XXX be We for

market So capture to of opportunity. dispenser, million to can of with into companion should reading the our between having potential very multi-billion is from about of we undesirable. the are and to instances as potential glasses, as excited we for prior who Optejet key be look is a you highly product MicroLine U.S. people on-demand vision. MicroLine XX of dollar be difficulty glasses VISION-X also believe benefits growth. MicroLine but the the approved. significant our alone, XX ages the In are of had wear readers plans long-term When we intended estimated clinical market This an driver XX, presbyopia, to never a near and results, who suffer our share translates for inconvenient using there at a or the when

Sean drug modify caused the FDA, to which response available product the response MydCombi working the made by we device letter. complete reclassification, versus FDA, is Genus to on website. on their resubmission which combination to more Medical to of from case our information mentioned, recent team a initial our our of a triggered was classification in drug about court As Technologies FDA the a The have

required of conducted should studies, of not would not drug under laboratory types the with report degrade reports not the demonstrate FDA capabilities life. drug Optejet the One is that that over be did -- under example for Specifically, a its requesting the not a required were We period reports was these submission. device submission. routinely a certain studies NDA, of MydCombi shelf validation that validation because not but device submit the it

The CRL work we and it We emphasize issues or no Now other packaging or with the for with we along has taking cannot impact have efficacy product this enough. no safety are and results our programs. clinical resubmission. the done on this CRL information other raised our

MicroLine broader have programs of as programs late-stage of dispensing implications Optejet other technology, leverage positive to MicroPine. our reclassification combination as These device streamline the also drug future As mentioned, development Sean a MydCombi microdose for may the and a well review technology. platform

to programs. offer So developed Eyenovia is with very a that to providers we multi-billion our the as benefits drug information This develop multiple shareholders. sales with forward transferable programs great and filing continue the for dollar summary, presbyopia, keenly being for is device MicroLine likely combination potential late-stage patients, support moving important a on is across these fronts potential. In program

update We forward excited on and our John Financial and are bring our therapeutic of would of MicroPine, providing progressing a approval brief to to to the potential the weeks John? like call focused updates look I agreements, as light status about focus a licensing on programs as months. well financial update. the possible including monitoring. technology in Officer, these in as Chief now potential the recent turn on provide benefits regulatory the can over additional efficiently our We remote to to remain Gandolfo as coming

John Gandolfo

more. randomized I Michael. in brief for start of reduction can FDA pediatric detachment, vision for Vision contact three you, agree they our part to Bifocal this drugs Phase Bausch slow South for XX% related the to myopia myopia our prescribed children. formulation myopic MicroPine left untreated, lenses costs if Recall assume by in agreements typically and been and licensing the the in to proprietary that multifocal CHAPERONE with There oversight the indication, of and retinopathy, shown or clinical or studies approved has glasses this ongoing or are as is result loss. agreement X Enrollment Health, is progression. to China myopia Thank than between trial trial. Health XXX therapies progression drug trial Korea. no currently retinal will U.S.-based and are that for progressing in comparing years This is as microdose It clinical Canada of is solution. with a planned. MicroPine all children MicroPine The double-masked XX-month with years enrolling versus is and and Arctic XX update U.S. a multicenter Bausch of placebo age. of three atropine X.X% more a ophthalmic

original China covers agreement MicroPine with Arctic MydCombi from agreement And also and well. Greater Our Korea. was Vision and South recently they added the MicroLine, as while

current So programs. Arctic Vision of now three accesses our all

preparing and PK its a pleased accepted are in Phase that MicroPine to X Arctic had their start Vision We study. IND completing recently China, is study and

have and reimbursable expenses are partners $XX is progressing licensing agreements To-date program Development earn an geographical license can approved, Upon progress sales potential approximately nicely. significant in also of development to progressing territories. license over if have additional and generated the that million as So our license $XX also fees next well. other we four the million milestones, and and earn commercialization, we additional for is royalties key seeking years. we

ophthalmic and as We’re we leverage expansion additional address continuing opportunities, needs pipeline to large unmet potential assess believe technology Optejet indications. the can also to we

examples As significant dry anti-infectives, and eye with include market we indicated anti-inflammatories, opportunities. last glaucoma, quarter, each some

like the financial months our for three review XX, would ended September XXXX. to I results Now,

totaled of outstanding. For approximately compares million $X.X the this the third or per reported $X.XX for third $X.X XX.X increase approximately of million of million of approximately XXXX, for XX.X the the per XXXX and quarter XXXX weighted an of same approximately of outstanding XXXX, quarter share average approximately a and for expenses net average period shares weighted million this to R&D shares approximately on in on third $X.XX $X.X million quarter X.X%. to or compares loss share a we net approximately loss million $X.X

were of approximately same of This of million also XXXX, quarter XX.X%. $X.X the approximately $X.X approximately an increase the million, the approximately of for third $X.X an XXXX. expenses XXXX, compared approximately with of third expense. Operating expenses expenses XX%. $X.X in for stock non-cash to total expenses compensation operating G&A third million, increase for compared quarter represents operating period were of million included the of quarter XXXX Total approximately For $XXX,XXX

million. XXXX, and company’s As XX, of was cash balance unrestricted September approximately restricted the $XX.X

this To Our MydCombi. product MydCombi company through and launch, X reduced be sufficient Phase launch for with be advance of the our fund expected resources cash the programs data to complete continuing and MicroLine to approximately all recently pilot with mydriasis of delayed to preparation will through second current the our in XXXX, rapidly X are program with cash topline Therefore, resources current In to-date. we we closing, expect our VISION-X, spending manufacturing initiated Phase clinical anticipated cash our highlights and performance believe the unrestricted with to facility. presbyopia and we our the we due that today, continue provides sufficient NDA process million bring $XX presbyopia complete key of program. our summarize restricted trial to We the mid-XXXX. out commercial pleased are

We of first Optejet quarter if us give approved, technology. year, the in validate product our our are would actively our dispensing preparing resubmission and first of for the commercial which next MydCombi NDA

That agreements call Bausch believe well like to We development regulatory concludes shareholders and prepared with for and and use achieve catalysts expand are advance next positioned potential this Arctic offer development We to year dilutive continue milestones, leveraging meaningful licensing our the our of commercial Vision we questions. Operator? for regulatory and are therapeutics non remarks. to funding and our that open potential MAP and we novel Our multiple benefit progressing Health would and to well of patients pipeline the technology. to can the alike. now

Operator

from Capital. question with Chiang Northland Our Instructions] is [Operator Tim you. Please proceed. Thank first

Tim Chiang

to do exactly any you -- reclassification? there maybe data resubmission and provide FDA you a have MydCombi, bit to have is talk to little to could safety additional with Sean also the resubmission? Thanks. the just that this there FDA you refile any basically with what for the Michael, Is the about

Dr. Sean Ianchulev

do This detail. we went either Tim. on to don’t take has provide we in the as side, But some more Sean. the with we’re that and think validation which really nothing exactly verification deal activities concerns safety mentioned answer much to Michael It’s we is there that has granularity. of I the and efficacy or and to I’ll can points, think, Hi, think required It’s procedural to clearly I can try device clinical nature it data. nothing the your that. into it’s is that I type really familiar. very too with

we that device have But, that very a as we’ve the not clinical In so quality and validation call or reason. device, that we really very change maintained quick of dual the again, utility we’re It’s doesn’t too can works FDA, signed the device. coordinate it have the with fully go and into But, to we’re on how for make of the possible. systems to resubmission the detail, about for verification --, the fact, single working and the actively are item performance as understand every going the clinical we because much mostly performance. anything

Tim Chiang

see. I

your that And maybe got study? effect. their of just the vehicles VISION-X efficacy comparable same about I think their or Do received in XX% I sort rates approval, looking and take label, in that you’ll the from with as give have versus the effect effect was treatment you I treatment Okay. around, know, Obviously, Allergan MicroLine you’ve up. what follow product, pilocarpine of recently at then don’t product the studies one guess, treatment

Dr. Sean Ianchulev

Right.

going and overall VISION-X available. But on flip those the are the publicly quickly two. to very have our results speculate and side, study I about in So to VISION-X really very on we’ve that hesitate we’re data would soon. reported the

X% study in to is really is is for optimistic There to comes from they get topical the is There we the of rate to able quicker only technology less Ginger quickly, than as field think, high XX% And enroll appreciate treatment to headaches, VISION-X, we we such And than eyedropper, or it there overdose that I sites very really when site, is particular this study, XX%. with we’ll in competition that that availability especially the even how in interest the patients. fairly a that unique such XX%, into the the are the because with is which presbyopia. the be high competing more operations of know reported particularly indication. vicinity of VISION-X. team a in the Optejet, the got of

things again, hope VISION-X a we encouraged there’s So, and lot when to data. MydCombi we our very ultimately, that we’ve will, the excited our seen part and I that we’re think, VISION-X. address with very by of once validate We therapy. on reported the the presbyopia want that for impact will way it Allergan follow program and is the therapy really not validating pharmacologic excited And developing that for on pilocarpine us. in that we’re market, space now the any And as

Tim Chiang

All right.

Okay.

Michael Rowe

to to add Tim, something I’m Tim, actually -- that. I want

Tim Chiang

Sure.

Michael Rowe

XX between in I can cell You approval. two correctly three my But improvement XX%. and phone. of this that for the pointed what’s placebo out my difference letter be phone FDA was read and the required a the can’t delta line lines That’s read XX between cell character the I can improvement market, given

do, have our you the But product many to benefit vision the benefit. you to that bar even for actual functional bar the that to more have on-demand benefit is to from functional get patient which will lower for to an high. have or example, patients over you a many, very your with barrier get get So approval, for the

are So, there’s there’s to patients clear, just -- -- just is make be what’s what happy want going by FDA to required that it it with. I versus the

Tim Chiang

That’s Thanks, color. Sean. for helpful. Okay. really that Michael, additional Thanks,

Michael Rowe

Sure.

Operator

question is Ladenburg Thalmann. proceed. next Our with Kaplan from Please Matt

Matt Kaplan

you already refiling validation follow Thanks questions. the just and in wanted where so for to think? to with in be on you or refile? you more do you work up are at do guys. have novo much de the hand, to your and for need process scratch you how MydCombi? If from guess Hey, the I taking end to able to verification, look that data I that respect from

Michael Rowe

Michael. It’s there. Hey,

XX% it’s to be XX% we we then be. already. and may we clinical of do to study, that probably where to match validation it have like to that And Reg have We’re just done -- not studies we back it say had up don’t, the a rewrite might look and going regulation I whatever would the that it finding

in all validation clinical is going any that really need the that. already So through piece right and blanks a of we just of where there’s in nothing or there terms be reports fill do. it to we’ve missing, that And done two we the for now might

Matt Kaplan

And great. your That’s expectation terms in of at refile what’s you when with Class the Okay. you this X or X Class point?

Dr. Sean Ianchulev

Yeah.

The So, in that or Matt, made team part have review device when best what fact I that’s because next it that Michael part this, and the of and FDA how is what the has unclear with of I feedback one the in And absolutely additional device it verification/validation, anybody given answer don’t device in this additional but this encouraged ultimately, line in made. to data, their would and less to speculate specifications, we’ve with side. field reviewer our probably have systems hate said, side. know When to never we to team, on we the we be would the discussions the does we’ve time we how be all and and more has they FDA lot do quality we’ve been. expectations, love an processes the from what because control device very us from regulations is it comes have utilization the systems, because now. and be correct, we’re FDA. said than acceptable engineering to data. the and because partially our patient. really call And we’ve with built our some of And majority is, by or the It that really from a reclassifies all following is also that and the the do would have from had have your own always will will that quality a of obviously appropriate used make us be we’ve to it by before, fact created the maintained developed how the the not

again, FDA not we things it’s to very and that out always we turn before, may a have absolutely specific before want quickly, to that regulations couple showing all we the true. them important information a that that thing. may be of easy points back have very intend something So, you come that. them sure to with to But provide it’s information to we we can having there’s back or It very or feedback already may dealt get to the and expedite addressing their make with ascertain and

Matt Kaplan

terms Okay. That the I makes in versus differentiation presbyopia competitive up given MicroLine and follow about evolving other sense. programs of Thanks. programs? and the there. approval, on recent the program, talk space MicroLine the And then other Allergan of guess out Can you

Michael Rowe

be is the which patient’s of differentiation products going lifestyle. these best to The on Matt. Sure, match

their go their prescriber wear believe If These to into never been never you of who’ve because I offices these. generally they’ve are be had they optometrist glasses. patients life, entire and an principal will to the before,

to, trouble coming is and that vision minimal of and like to presbyopia side way to them product use effects that when so in with the -- near looking And they’re glasses. into glasses, like easy presbyopia they’re they with now differentiators. is want to easy something want what a disease. give the they options, for think would use will ability They don’t can manage like and that’s it’s they one for they’re what I something that’s a as because as having invisible looking would to not they’re they differentiation in and glasses, turn but to So MicroLine that biggest use

low Optejet use very dispenser to don’t ability medications see in done take real is. one all other somebody’s having into put number because a an research effect for all market them, convenient difference the easy right world really the to we’ve a in differentiator. every to of be the to be that’ll day, it have take the the now every third the side So day, would make their does. it when And And one once profile instead makes they people good It make do. the and on-demand would I which that technology have difference you That’s think the hands. you how to

Matt Kaplan

sense. Sean. Michael. Okay. Thanks. Thanks, Makes Thanks,

Dr. Sean Ianchulev

you. Thank

Operator

question next Len Partners. Please proceed. Stoc*Doc with is from Our Yaffe

Len Yaffe

is they’re reading Yeah. in a is of it being MicroLine wear over and want as much. to out be where go the talked that, relates it incidence again, And Mike such just to a think to point is side gain. is be have product very therefore, cosmetic the before because this photographed as feel using going wanted you critical to what restaurant bad you’ve to want not cosmetic social you to as about an where Sean, have to or having often greatest cosmetic Thank I people glasses. don’t with situations, they the deterrent, people to for effects a to don’t be photographed and going event at glasses a with going are

included greater obviously, just their adverse the that understand differentiation? Could to difference. Allergan, So hyperemia. vision, equal that blurred events you at as significant it important eye event adverse an wondering, much. a and be this to X% you’ve relates would I think in hyperemia they’re headache, you than trial I And extent and discuss so profile that as photographed, was being with specific is your to Thanks their pain seen

Michael Rowe

cause because Sure, Len. hyperemia, doesn’t pilocarpine with I’ll hyperemia. generally start

to up because at up our look least showed up mile we their showed in trial people in showed for it. even though traced and ours, case, it in it So a asked

cases, something So specifically hyperemia. very said and a see think investigators traced any do you And disappeared transit then that for like of asked quickly. yes, news mile we the they XX% I

much the how in much drug, is -- and ache the to you up get because what headache it gets eyes the to ache, brow you the that you the think to and give. to relation you is is going one and put on directly and or be the into I directly big relation local is related that’s brow that the drugs how tensing put drugs happens excess eye, muscle between circulation

was classified because trials people trial, with something in in see, Allergan minimal, which that, much the a pilocarpine we what you brow And could what’s And probably headache to be that’s is agree be of or for putting bother believe would And in with. one even to saw, and drug for X% to transient headache their I you’re it’s as that, ache how you and have saw something but so want not graded most of our or about close I surprisingly, general, what expected. about XX.X%, in. don’t

differentiator and the of So a I Thank drop us the products. see as between you. that key --any

Len Yaffe

Okay.

up, follow a or pediatric myopia, you’ll as been just a study How think epidemic it phones. staying at it may relates then and do think, be where far competitively presbyopia? be computers positioned looking could be more versus with you as is think larger long do which, I any and you will who be that near-term this virtually inside at others progressive has market, so to by and an cell looking which worldwide kids And COVID-XX, exacerbated than

Michael Rowe

that’s required us, follow other There and two [ph] a a this staying the here the going come in they’re year eyedrops in there Yeah. That’s had with coming Raider part and just Orleans. are myopia was we ahead up at a the Eye products fourth I’m studies and because is panel then Shell And a great firm and big then FDA that. out are that a Sean Phase that question, of discussion. X. The and on a we just are are into years Nexus New three by of as Meeting Nevakar

if So Like patients are the be epidemic, a they’re a half years and of plenty new you all come patients said, behind years year millions we not and concerned it’s coming drops. going in, millions there’s there and or the year I’m kids, Number literally an out time. available. to one, a unfortunately, these particularly years of away. and are

systemic adherence less sting. itself going the track we using kind absorption, for drug, and to may and device from of also be it’s lower benefit. comfortable, benefits believe an we’ll it’s the in the compliance And can be drop atropine is you’re the Optejet can come if not and out because they kids, is of as which is, is kid to because the do that because they to taking some were that they’re switched, get of the then going which therapy atropine nice dispenser always therapy, a get often it’s more an not Secondly, the better I because mousetrap once it

else something that’s So as that can well. help them

So, that I me. a But again opportunity, we’ll probably number think, right now, big terribly that unfortunately, concerns be something three. not three, number such a it’s close

Len Yaffe

much. very Thanks Great.

Michael Rowe

Thank you.

Operator

like Sean to further remarks. closing more I questions, the over would turn to no for conference With

Dr. Sean Ianchulev

forward the a and we’ll happy everybody quarter, in Yes. in and next listening season. Thank everybody for hopefully you update have information look Thank has to when more our lot holiday you. next we meantime

Operator

conference. Thank you. conclude today’s does This

your time your may You thank at disconnect and for this you participation. lines

Eyenovia (EYEN) 12 Nov 212021 Q3 Earnings call transcript